- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ascendis Pharma AS ADR (ASND)
The Ascendis Pharma AS ADR share price today is 275.39, view NASDAQ ASND stock exchange data. Track the latest Ascendis Pharma AS ADR share price with real-time updates on ASND stock performance including market cap, day range, 52-week range and dividend yield. Access ASND charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
265.62
278.56
52 wk Range
188.08
282.15
ASND is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
265.62278.56
52 wk Range
188.08282.15
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ASND Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
303.21
Upside
+10.10%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
20 Buy
1 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 303.21
(+10.10% Upside)
Ascendis Pharma AS ADR SWOT Analysis
Pipeline Promise | Ascendis Pharma's innovative therapies for rare endocrine disorders show potential, with Yorvipath exceeding expectations and a promising achondroplasia treatment in development. |
Market Dominance | Explore Ascendis' first-mover advantage in hypoparathyroidism treatment, with Yorvipath projected to become a multi-billion euro drug in a market of 90,000 U.S. patients. |
Financial Trajectory | Delve into Ascendis' projected revenue growth from €363.6 million in 2024 to €1.72 billion by 2027, with analysts expecting profitability by 2026. |
Analyst Optimism | Learn about Wall Street's bullish stance on Ascendis, with price targets ranging from $170 to $250 and a highly favorable consensus rating of 1.25. |
Ascendis Pharma AS ADR Earnings Call Summary for Q3/2026
- Ascendis beat Q3 2026 estimates with EPS of $1.08 vs. $0.80 expected; revenue rose 89% YoY to EUR 366M driven by rare-disease portfolio growth.
- YORVIPATH revenue surged 103% YoY to EUR 291M; YUVIWEL doubled sequentially to EUR 16M in first full U.S. quarter with European launch pending.
- Operating margin improved to 42% as expenses fell EUR 32M QoQ; company raised 2026 operating cash flow guidance to at least EUR 600M from EUR 189M in Q3.
- Management reaffirmed long-term targets of EUR 5B revenue by 2030 and EUR 10B by 2035; plans to unveil new therapeutic area in 2027 supporting 2-3 products.
- Stock rose 0.49% to $260.55 in premarket, near 52-week high; company continues EUR 400M buyback program with EUR 330M completed and 2M shares repurchased YTD.
Last Updated: 12-11-2026, 07:58 pm
Read Full TranscriptEarnings
Latest Release
12-11-2026
EPS / Forecast
1.08 / 0.80
Revenue / Forecast
369.66M / 362.98M
Compare ASND to Peers and Sector
Metrics to compare | ASND | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipASNDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 18.7x | −3.0x | −0.2x | |
PEG Ratio | 0.04 | −0.10 | 0.00 | |
Price/Book | 10.9x | 2.3x | 2.6x | |
Price / LTM Sales | 13.6x | 6.3x | 2.8x | |
Upside (Analyst Target) | 11.1% | 116.9% | 63.4% | |
Fair Value Upside | Unlock | 7.3% | 9.5% | Unlock |
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Ascendis Pharma AS ADR (ASND) Share Price Today?
The Ascendis Pharma AS ADR share price today is 275.39.
What is the current Ascendis Pharma AS ADR (ASND) share price and day range?
As of 13-11-2026, the Ascendis Pharma AS ADR share price is 275.39, with a previous close of 267.07. The share price has ranged from 265.62 to 278.56 today, while the 52-week range spans from 188.08 to 282.15.
What Is the Ascendis Pharma AS ADR Market Cap?
As of today, Ascendis Pharma AS ADR market cap is 17.52B.
What Is the Ascendis Pharma AS ADR (ASND) Share Price Target?
The average 12-month share price target for Ascendis Pharma AS ADR is 303.21, with a high estimate of 339.13072329 and a low estimate of 258.65295289. 20 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +10.10% Upside potential.
What Is Ascendis Pharma AS ADR's Earnings Per Share (TTM)?
The Ascendis Pharma AS ADR EPS (TTM) is 15.70.
When Is the Next Ascendis Pharma AS ADR Earnings Date?
Ascendis Pharma AS ADR will release its next earnings report on 17-02-2027.
From a Technical Analysis Perspective, Is ASND a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Ascendis Pharma AS ADR Trade On?
Ascendis Pharma AS ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Ascendis Pharma AS ADR?
The stock symbol for Ascendis Pharma AS ADR is "ASND."
How Many Times Has Ascendis Pharma AS ADR Stock Split?
Ascendis Pharma AS ADR has split 0 times.
How Many Employees Does Ascendis Pharma AS ADR Have?
Ascendis Pharma AS ADR has 1189 employees.
What Is the ASND Premarket Price?
ASND's last pre-market stock price is 267.50. The pre-market share volume is 810.00, and the stock has changed by 0.43, or 0.16%.
What Is the ASND After Hours Price?
ASND's last after hours stock price is 273.00, the stock has changed by -2.39, or -0.87%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.